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Temporary vertebral flow reversal by Mono Mo.Ma: 
a new proximal protection system in the treatment of recent
vertebral artery occlusion
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A b s t r a c t
The major concern in performing percutaneous procedures for the treatment of vertebrobasilar obstructive disease is the risk of
embolic phenomena. We describe the successful treatment of a symptomatic patient with bilateral vertebrobasilar disease utilizing
a new proximal protection device, Mono Mo.Ma.
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S t r e s z c z e n i e
Głównym ograniczeniem zabiegów przezskórnej rewaskularyzacji tętnic kręgowych jest zjawisko embolizacji okołozabiegowej
do tętnic mózgowych zaopatrujących tylny krąg unaczynienia mózgu i ryzyko wystąpienia udaru mózgu. Opisano zabieg skutecznej
rekanalizacji tętnicy kręgowej u chorego z obustronną niedrożnością tętnic kręgowych i objawami niedokrwienia mózgu z wykorzy-
staniem nowego systemu protekcji mózgowej Mono Mo.Ma i czasowym odwróceniem przepływu w tętnicy kręgowej.
Słowa kluczowe: niedrożność tętnicy kręgowej, system Mono Mo.Ma, stent uwalniający lek antyproliferacyjny, niedokrwienie tyl-
nego kręgu unaczynienia mózgu
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Case report/Opis przypadku
Introduction
Ischaemic strokes related to posterior fossa ischaemia
(PFI) account for 25% of all transient ischemic attack (TIA)
or ischaemic stokes, and they portend a mortality rate of
20-30% [1]. As two vertebral arteries (VAs) usually supply
blood to the posterior cerebral circulation, the loss of one
is usually compensated by the sufficient antegrade flow in
the other. Thus, ischaemic symptom occurrence is usually
associated with bilateral occlusive VA disease or cerebral
embolisation. In the vast majority of cases, when the cause
is identified, a safe revascularisation procedure is ques-
tionable or impossible due to bilateral occlusion or the sub-
stantial risk of thrombus or plaque debris embolisation dur-
ing the endovascular revascularisation procedure. 
Case report
We present a case of a 69-year-old man with a 4-week
history of posterior fossa ischaemia, with a left occipital
ischaemic stroke due to bilateral VAs occlusion with recur-
rent headache, progression of visual disturbances, mem-
ory deficits and orientation problems. 
Neurological examination revealed right-sided homony-
mous hemianopia and alexia (MMSE 18 points). Unen-
hanced head CT scan demonstrated left occipital lobe
infarct without signs of haemorrhage. 
Additionally, his medical history revealed ischaemic
heart disease, arterial hypertension, hypertriglyceridaemia,
diabetes mellitus, prior left renal artery stenting and chron-
ic atrial fibrillation. 
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Three weeks after the first episode of cerebral is -
chaemia, the patient was transferred to our cardiology and
vascular department for further assessment due to sig-
nificant heart rhythm disturbances on Holter ECG moni-
toring in the presence of left ventricle contractile dys-
function, as a potential cause of intermittent neurological
symptoms gradually arising during the last weeks. 
In our department, duplex ultrasonography demon-
strated non-significant carotid artery disease, and proxi-
mal occlusion of the right VA and near-occlusion of the left
VA, with bilateral collateral circulation from the thyrocer-
vical trunk.
Echocardiography confirmed markedly reduced left ven-
tricle ejection fraction to 35% with spontaneous echo con-
trast in left heart chambers, as well as mild mitral and aor-
tic insufficiencies. 
Coronary angiography demonstrated chronic proximal
right coronary artery occlusion with good collateral flow from
the non-obstructed branches of the left coronary artery. Dur-
ing the same session, selective VA arteriography confirmed
ostial occlusion of the right VA (Figure 1) and ostial 8 mm
long near-occlusion of the left VA, with significant collater-
al flow from the left thyrocervical trunk (Figure 2). 
Taking into consideration the intermittent neurologi-
cal symptoms, a consultant neurologist was asked to re-
assess the patient’s status, and he diagnosed intermittent
symptoms of posterior fossa ischaemia related to bilater-
al VA occlusive disease. Further patient management was
discussed by the multidisciplinary team including a cardi-
ologist, invasive cardiologist, vascular surgeon and neu-
rologist, and in consequence the patient was referred for
endovascular recanalisation of the left VA. 
The patient was typically pre-treated with dual
antiplatelet therapy (aspirin 75 mg/day and clopidogrel 
75 mg/day). Vascular access was gained via the femoral
approach. Considering the high risk of thrombus presence
in the occluded portion of the artery, we decided to create
a temporary stop flow in the subclavian artery (SA) to pre-
vent possible cerebral embolisation and embolic stroke dur-
ing catheter manipulations within the left VA. 
We used a new variant of a proximal protection device
system – Mono Mo.Ma Ultra (Medtronic Inc. Parkway, Min-
neapolis MN USA), dedicated to proximal protection dur-
ing carotid stenting of the internal carotid artery (ICA) in
the presence of ipsilateral external carotid artery occlusion. 
After the Mono Mo.Ma cerebral protection device was
placed in the proximal left SA, blood flow was arrested by
expanding the device balloon (Figure 2 C). An attempt of
typical recanalisation with a 0.014” Whispear (Abbott Vas-
cular, Redwood City, CA, USA) coronary wire was unsuc-
cessful due to insufficient support in the wide SA. After
many attempts, we decided to use a 5 F Judkins Right 4.0,
125 cm length catheter (Cordis, Johnson&Johnson Com-
pany, Miami Lakes, FL, USA) introduced through the main
channel of the Mono Mo.Ma system device. The tip of this
catheter was directed into the visible stump of the occlud-
ed left VA, providing good support for wire recanalization.
The occlusion site of the left VA was crossed with a HT
BMW 0.014” 300 cm wire (Abbott Vascular) (Figure 2 D).
Then, the Judkins catheter was removed and pre-dilation
with a rapid exchange Sprinter Legend 2.5/15 mm
(Medtronic, Inc. Minneapolis, MN, USA) coronary balloon
catheter was performed (Figure 2 E). 
Immediately afterwards, reverse flow in the left VA was
detected (Figure 2 F). A Resolute 3.0/18 mm (Medtronic)
drug-eluting stent was implanted in the stenotic portion
of the vessel with a typical stent protrusion to the SA. After
stent deployment with 12 atm, the balloon was partially
withdrawn and ostial flaring with 16 atm was performed. 
The whole stenting procedure was performed under
the protection of iatrogenically inverted vertebral flow,
which was confirmed angiographically (Figure 2 F). Before
deflation of the Mono Mo.Ma system, a typical aspiration
with 2 syringes was performed. The final angiography
showed proper stent deployment and optimal antegrade
flow in the left VA (Figure 2 H). No periprocedural or post-
procedural complications were observed. The patient was
discharged from the hospital with recommendations of
Fig. 1. Baseline selective angiography of the right
subclavian artery showing occlusion of the right
vertebral artery
Ryc. 1. Angiografia prawej tętnicy podobojczykowej
– niedrożność prawej tętnicy kręgowej 
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dual antiplatelet therapy for at least 12 months, statin, pro-
ton pump inhibitor, calcium channel blocker, ACE inhibitor,
torasemide, and spironolactone. 
The post-procedure neurological assessment demon-
strated symptom resolution, with only mild visual loss.
Discussion
The use of protection systems during VA procedures is
not routinely recommended, as opposed to ICA stenting.
Studies employing transcranial Doppler and diffusion-
weighted magnetic resonance imaging (MRI) have docu-
mented microembolization during interventional proce-
dures [2-4]. Furthermore, the frequency and amount of
captured emboli during stent procedures in ICA and ostial
VAs seem comparable [5, 6]. However, when protection is
used, most authors use distal protection systems, partic-
ularly in the presence of VA lesions containing thrombus
or very soft and ulcerated plaques [7, 8].
We have previously described a case of impending
stroke with marked symptoms of posterior fossa ischaemia
due to floating thrombus in the left VA origin, successful-
ly treated with angioplasty, where flow reversal in the left
VA was achieved with a guiding catheter of the Flow Rever-
sal Gore Neuroprotection System (W.L. Gore&Associates,
Flagstaff, AZ, USA) [9]. This technique was also success-
fully used in several cases of high-risk SA lesions involving
origin of the VA [10, 11]. In high-risk SA stenting requiring
covering of the VA origin, proximal protection is the only
one to be employed as a filter device could not be removed
from the VA after stent implantation to the SA.
Proximal protection through flow reversal creation in
the VA seems to be very desirable in terms of patient safe-
ty. The only risk of this technique is upper limb artery
embolisation by debris washed out from the VA by the
reverse flow. However, due to rich collaterals in palmar arch
arteries, the risk of upper limb ischaemia is rather negli-
gible.
This novel Mono Mo.Ma system dedicated to ICA stent-
ing in the presence of ipsilateral external carotid artery
occlusion has 8 F size, whereas GORE NPS is substantial-
ly bigger and bulkier (10 F). Thus, in cases of very high-risk
VA and/or SA angioplasty, Mono Mo.Ma system protection
seems reasonable and it may be recommended. 
The other aspect worth considering is the use of drug-
eluting stents for VA stenosis. As the restenosis rate after
VA balloon angioplasty or coronary bare-metal stent place-
ment is remarkably high (up to 50%), it constitutes
a severe drawback of VA endovascular procedures [12-14].
Recent reports have suggested decreased restenosis rates
with drug-eluting stents to 7-8.5% at 12 months and 17%
at 21 months, as compared to 23.1% and 38% respective-
ly, in patients who received bare metal stents [15-17]. Tak-
ing into consideration these data, in the presented patient,
we applied a drug-eluting stent, despite the lack of guide-
Fig. 2. A – Baseline selective angiography in an early phase of contrast agent administration of the LVA show-
ing near occlusion of the ostium (arrow). B – Late image frames showing LVA filling from the collateral flow
(arrows). C – Mono Mo.Ma emboli protection device in the proximal portion of the left subclavian artery. 
D – Successful crossing of the occlusion site with a HT BMW 0.014” 300 cm wire. E – LVA after pre-dilation with
a rapid exchange Sprinter Legend 2.5/15 mm coronary balloon catheter. F – Visible flow reversal from LVA to the
left subclavian artery. G – Stent in position prior to deployment. H – Final angiographic result of the LVA stenting
Ryc. 2. Angiografia lewej tętnicy podobojczykowej. A – wczesna faza podania kontrastu – subtotalne zwężenie
lewej tętnicy kręgowej, B – późna faza podania środka cieniującego – wypełnianie tętnicy kręgowej poprzez krąże-
nie oboczne, C  – balon systemu Mono Mo.Ma rozprężony w proksymalnym odcinku tętnicy podobojczykowej, 
D – sforsowanie niedrożności prowadnikiem HT BMW 0,014, 300 cm, E – LVA po predylatacji balonem Sprinter
Legend 2,5/15 mm, F – widoczne ujemne kontrastowanie tętnicy podobojczykowej wywołane odwróceniem przepły-
wu w LVA, G – pozycjonowanie stentu w LVA, H – obraz LVA po implantacji DES i deflacji systemu protekcji
A B C D E F G H
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lines concerning this issue. The drawback of drug-eluting
stents may be a need of prolonged dual antiplatelet ther-
apy. However, the duration of such treatment is extrapo-
lated from data available from the coronary field, due to
completely missing data concerning timing of dual
antiplatelet therapy after VA stenting. 
In conclusion, it seems that the proximal protection
device Mono Mo.Ma can be used safely and effectively in
high-risk angioplasty of the VA.
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